Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Interest & Investment Income (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Interest & Investment Income data on record, last reported at $3.5 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 3.12% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $13.1 million, up 2.9%, while the annual FY2025 figure was $13.1 million, 2.9% up from the prior year.
  • Interest & Investment Income reached $3.5 million in Q4 2025 per APLS's latest filing, down from $4.4 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $6.0 million in Q2 2023 and bottomed at $37000.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $2.8 million, with a median of $3.0 million recorded in 2024.
  • Peak YoY movement for Interest & Investment Income: plummeted 94.11% in 2021, then skyrocketed 12264.86% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $37000.0 in 2021, then surged by 12264.86% to $4.6 million in 2022, then fell by 0.57% to $4.5 million in 2023, then fell by 25.35% to $3.4 million in 2024, then rose by 3.12% to $3.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $3.5 million in Q4 2025, $4.4 million in Q3 2025, and $2.6 million in Q2 2025.